For the year ending 2025-12-31, BRTX made $359.7K in revenue. -$14,241.975K in net income. Net profit margin of -3959.40%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenues | 359.7 | 401 | ||
| Cost of goods sold | 23.844 | 28.072 | ||
| Gross profit | 335.856 | 372.928 | ||
| Research and development | 10,094.671 | 5,348.709 | ||
| General and administrative | 5,888.317 | 6,579.413 | ||
| Total operating expenses | 15,982.988 | 11,928.122 | ||
| Loss from operations | -15,647.132 | -11,555.194 | ||
| Interest income, net | 266.207 | 616.077 | ||
| Other income | 17.448 | 150.85 | ||
| Change in fair value of warrant liabilities | 1,121.502 | 97.188 | ||
| Gain on exchange of warrants | - | 1,711.698 | ||
| Total other income | 1,405.157 | 2,575.813 | ||
| Net loss | -14,241.975 | -8,979.381 | ||
| Basic EPS | -1.58 | -1.16 | ||
| Diluted EPS | -1.58 | -1.16 | ||
| Basic Average Shares | 8,993,115 | 7,763,932 | ||
| Diluted Average Shares | 8,993,115 | 7,763,932 | ||
BioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. (BRTX)